Opinion
Video
Examining Combination Therapy In NF1-PN
Panelists discuss the exploration of combination therapies in treating complex or refractory NF1-associated plexiform neurofibromas, including MEK inhibitors combined with PI3K inhibitors, anti-angiogenic agents, and chemotherapies, and review early clinical findings suggesting potential synergistic effects, while highlighting concerns about toxicity and the need for careful patient monitoring.
Summary for Physicians
Combination Therapies in NF1-PN
For more complex or refractory neurofibromatosis type 1–associated plexiform neurofibromas (NF1-PN) cases, combination therapies are being explored to enhance therapeutic efficacy. Studies have investigated combinations of MEK inhibitors (eg, selumetinib) with other targeted agents, such as PI3K inhibitors, anti-angiogenic agents, and chemotherapies. The rationale behind these combinations is to target multiple pathways involved in tumor growth and progression, potentially improving response rates and reducing the risk of resistance.
Observed Results
Early clinical trials and preclinical studies suggest that combination therapies can result in synergistic effects, leading to better tumor shrinkage and symptom control compared to monotherapy. However, toxicity and adverse effects are a concern, especially with combinations that involve multiple agents, requiring careful patient monitoring.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
